Page last updated: 2024-12-05

fenthion

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Fenthion: Potent cholinesterase inhibitor used as an insecticide and acaricide. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

fenthion : An organic thiophosphate that is O,O-dimethyl hydrogen phosphorothioate in which the hydrogen atom of the hydroxy group is replaced by a 3-methyl-4-(methylsulfanyl)phenyl group. It exhibits acaricidal and insecticidal activities. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID3346
CHEMBL ID1604375
CHEBI ID34761
SCHEMBL ID26907
MeSH IDM0008341

Synonyms (202)

Synonym
AC-16722
BIDD:ER0528
fenthion (mpp)
BRD-K67217586-001-02-3
phosphorothioic acid, o,o-dimethyl o-[4-(methylthio)-m-tolyl] ester
phosphorothioic acid, o,o-dimethyl o-[3-methyl-4-(methylthio)phenyl] ester
DIVK1C_006646
o,o-dimethyl o-[3-methyl-4-(methylthio)phenyl] thiophosphate
SPECTRUM_001919
BSPBIO_002469
SPECTRUM5_002028
entex
NCGC00091635-01
fenthion
C14420
55-38-9
4-methylmercapto-3-methylphenyl dimethyl thiophosphate
o,o-dimethyl-o-4-(methylmercapto)-3-methylphenyl phosphorothioate
mpp (pesticide)
o,o-dimethyl o-(4-methylthio-3-methylphenyl) thiophosphate
bayer 9007
o,o-dimethyl o-(3-methyl-4-(methylthio)phenyl)phosphorothioate
dimethyl o-(4-(methylthio)-m-tolyl) phosphorothioate
bay-bassa
baycid
lebaycid
tiguvon
dimethyl (3-methyl-4-(methylthio)phenyl) phosphorothionate
o,o-dimethyl o-3-methyl-4-methylthiophenyl phosphorothioate
talodex
figuron
fenthion 4e
bayer 29493
o,o-dimethyl-o-(3-methyl-4-methylthiophenyl)-monothiophosphat [german]
o,o-dimethyl-o-[4-(methylthio)-m-tolyl] phosphorothioate
brn 1974129
o,o-dimetil-o-(3-metil-4-metiltio-fenil)-monotiofosfato [italian]
o,o-dimethyl o-(3-methyl-4-methylthiophenyl) thiophosphate
o,o-dimethyl o-(3-methyl-4-methylmercaptophenyl)phosphorothioate
ent 25,540
o,o-dimethyl o-(4-methylmercapto-3-methylphenyl) thionophosphate
fenthion [bsi:iso]
einecs 200-231-9
bayer s-1752
oms 2
epa pesticide chemical code 053301
fenthione
dimethyl methylthiotolyl phosphorothioate
pro-spot
fenthion-methyl
o,o-dimethyl o-(4-methylthio-3-methylphenyl) phosphorothioate
nci-c08651
o,o-dimethyl o-(3-methyl-4-methylthio-fenyl)-monothiofosfaat [dutch]
spotton
thiophosphate de o,o-dimethyle et de o-(3-methyl-4-methylthiophenyle) [french]
phenthion
ai3-25540
o,o-dimethyl-o-(3-methyl-4-methylmercaptophenyl)phosphorothioate
o,o-dimethyl-o-(3-methyl-4-methylthio-phenyl)-thionophosphat [german]
bay 29493
o,o-dimethyl o-(4-(methylthio)-m-tolyl) phosphorothioate
queletox
b 29493
caswell no. 456f
o,o-dimethyl-o-(3-methyl-4-methylthio-fenyl)-monothiofosfaat [dutch]
phosphorothioic acid, o,o-dimethyl o-(4-(methylthio)-m-tolyl) ester
dimethyl o-(3-methyl-4-(methylthio)phenyl) thiophosphate
hsdb 1403
sulfidophos
ccris 310
s 1752
mosquitocide 700
lebayeid
m-cresol, 4-(methylthio)-, o-ester with o,o-dimethyl phosphorothioate
fenthion, analytical standard
o,o-dimethyl o-4-methylthio-m-tolyl phosphorothioate
o,o-dimethyl o-[3-methyl-4-(methylsulfanyl)phenyl] thiophosphate
o,o-dimethyl-o-4-(methylmercapto)-3-methylphenyl thiophosphate
phosphorothioic acid, o,o-dimethyl o-(3-methyl-4-(methylthio)phenyl) ester
mercaptophos
CHEBI:34761 ,
o,o-dimethyl o-4-(methylmercapto)-3-methylphenyl phosphorothioate
o,o-dimethyl o-[3-methyl-4-(methylsulfanyl)phenyl] phosphorothioate
NCGC00091635-02
NCGC00091635-03
NCGC00091635-04
KBIOGR_001189
KBIO2_005022
KBIO3_001969
KBIOSS_002461
KBIO2_002454
KBIO2_007590
KBIO1_001590
SPBIO_001102
SPECTRUM2_001231
SPECPLUS_000550
SPECTRUM3_000855
SPECTRUM4_000695
SPECTRUM330064
baytex
NCGC00091635-06
NCGC00091635-05
MLS002695988
smr000777965
D07950
fenthion (ban)
tiguvon (tn)
inchi=1/c10h15o3ps2/c1-8-7-9(5-6-10(8)16-4)13-14(15,11-2)12-3/h5-7h,1-4h3
pnvjtzofshslto-uhfffaoysa-
dimethoxy-(3-methyl-4-methylsulfanylphenoxy)-sulfanylidenephosphorane
NCGC00091635-08
NCGC00091635-07
HMS3264I08
HMS3091A22
NCGC00254566-01
tox21_201595
tox21_300658
NCGC00259144-01
nsc-755881
nsc755881
pharmakon1600-00330064
tox21_111157
dtxsid8020620 ,
cas-55-38-9
dtxcid00620
CHEMBL1604375
CCG-39101
o,o-dimethyl-o-(3-methyl-4-methylthio-phenyl)-thionophosphat
bl0l45ovkt ,
nsc 755881
o,o-dimethyl o-(3-methyl-4-methylthio-fenyl)-monothiofosfaat
o,o-dimetil-o-(3-metil-4-metiltio-fenil)-monotiofosfato
unii-bl0l45ovkt
o,o-dimethyl-o-(3-methyl-4-methylthiophenyl)-monothiophosphat
o,o-dimethyl-o-(3-methyl-4-methylthio-fenyl)-monothiofosfaat
thiophosphate de o,o-dimethyle et de o-(3-methyl-4-methylthiophenyle)
fenthion [inn:ban]
FT-0603232
AKOS015889922
fenthion [iso]
fenthion [hsdb]
fenthion [mi]
fenthion [green book]
o,o-dimethyl o-(3-methyl-4-(methylthio)phenyl) phosphorothioate
fenthion [mart.]
SCHEMBL26907
NCGC00091635-09
tox21_111157_1
o,o-dimethyl o-[3-methyl-4-(methylsulfanyl)phenyl] thiophosphate #
o,o-dimethyl-o-(3-methyl-4-methylthiophenyl)-monothiophosphate
o,o-dimethyl-o-(3-methyl-4-methylthio-phenyl)-thionophosphate
ent 25540
mpp (pestiide)
o,o-dimethyl o-[3-methyl-4-(methylthio)phenyl]phosphorothioate
AB00053057_04
fenthion d6
methyl 3-methyl-4-(methylsulfanyl)phenyl methoxy(sulfanylidene)phosphonite
SR-01000872733-1
sr-01000872733
fenthion, pestanal(r), analytical standard
fenthion 10 microg/ml in cyclohexane
o,o-dimethyl o-[(3-methyl-4-methylthio)phenyl] phosphorothioate, 9ci
SBI-0052549.P002
o,o-dimethyl o-3-methyl-4-(methylthio)phenyl phosphorothioate
Q418354
DB11412
BRD-K67217586-001-04-9
fenthion 1000 microg/ml in acetone
o,o-dimethyl o-[3-methyl-4-(methylthio)phenyl]thiophosphate
fenthion 1000 microg/ml in toluene
dimethoxy-(3-methyl-4-methylsulfanylphenoxy)-sulfanylidene-lambda5-phosphane
F1310
E85601
phosphorothioic acid, o,o-dimethyl o-[3-methyl-4-(methylthio)phenyl]ester
o,o'-dimethyl o′-[3-methyl-4-(methylthio)phenyl] thiophosphate
1ST20065
o,o-dimethyl-o-(3-methyl-4-methylthio)phenyl)phosphorothioate
spotton 20% ready-to-use cattle insecticide
phosphorothioic acid, o,o-dimethyl-, o-(4-methylthio)-m-tolyl ester
dimethyl 4-methylthio-m-tolyl phosphorothioate
phosphorothioic acid ((h3po3s)), o,o-dimethyl o-4-(methylthio)-m-tolyl ester
o,o-dimethyl o-(3-methyl-4-(methylsulfanyl)phenyl) thiophosphate
phosphorothioic acid o,o-dimethyl o-(3-methyl-4-(methylthio)phenyl) ester
o,o-dimethyl-o-3-methyl-4-methylthiophenyl phosphorothioate
phosphorothioic acid, dimethyl (4-(methylthio)-m-tolyl) ester
o,o-dimethyl o-(4-(methylthio)-m-tolyl) thiophosphate
o,o-dimethyl-(o-(4-methylthio)-m-tolyl)phosphorothioic acid ester
o,o-dimethyl-o-(4-methylthio-m-tolyl) phosphorothioate
o,o-dimethyl o-(3-methyl-4-methylmercaptophenyl) phosphorothioate
tiguvon pour-on cattle insecticide
o,o-dimethyl o-4-(methylmercapto)-3-methylphenyl thiophosphate
pro-spot solution
o,o-dimethyl-o-(4-(methylthio)-m-tolyl)phosphorothioate
hebaycid
o,o-dimethyl o-(3-methyl-4-(methylthio) phenyl) es
o,o-dimethyl o-(3-methyl-4-(methylsulfanyl)phenyl) phosphorothioate
o,o-dimethyl )-(4-methylmercapto-3-methylphenyl) thionophosphate
o,o-dimethyl o-(3-methyl-4-(methylthio) phenyl) ester, phosphorothioic acid
queleton
fenthion (mart.)
phosphorothioic acid o,o-dimethyl o-
bayer 29 493

Research Excerpts

Overview

Fenthion (FEN) is an organophosphorus pesticide known for its wide toxic manifestations. Fenthion acts via inhibition of the enzyme cholinesterase.

ExcerptReferenceRelevance
"Fenthion (MPP) is a popular organophosphorus pesticide that acts via inhibition of the enzyme cholinesterase. "( Simultaneous determination of fenthion and its metabolites in a case of fenthion self-poisoning.
Arai, T; Hoshi, T; Nishio, T; Nogami, M; Toukairin, Y, 2023
)
2.64
"Fenthion (FEN) is an organophosphorus pesticide known for its wide toxic manifestations. "( Fenthion, an organophosphorus pesticide, induces alterations in oxidant/antioxidant status and histopathological disorders in cerebrum and cerebellum of suckling rats.
Ben Amara, I; Boudawara, T; Sefi, M; Soudani, N; Troudi, A; Zeghal, N, 2014
)
3.29

Effects

Fenthion is involved in a subacute type of OP-related neurotoxicity in patients. Fenthion has been the most common cause.

ExcerptReferenceRelevance
"Fenthion has been involved in a subacute type of OP-related neurotoxicity in patients, the so-called intermediate syndrome."( Electromyography in relation to end-plate acetylcholinesterase in rats poisoned by different organophosphates.
De Bleecker, J; De Reuck, J; Van den Abeele, K, 1994
)
1.01
"Fenthion has been the most common cause."( Acute and subacute organophosphate poisoning in the rat.
De Bleecker, J; De Reuck, J; Lison, D; Van Den Abeele, K; Willems, J, 1994
)
1.01

Actions

ExcerptReferenceRelevance
"Fenthion did not cause any alteration in SOD and CAT activities while increasing GSH content, GSH/GSSG ratio and GST specific enzyme activity and decreasing GSSG, TBARS, and protein contents."( N-Acetylcysteine provides dose-dependent protection against fenthion toxicity in the brain of Cyprinus carpio L.
Cinkiloğlu, E; Durmaz, H; Piner, P; Sevgiler, Y; Uner, N, 2009
)
1.32

Treatment

Fenthion pretreatment caused significant increases in the BPMC plasma concentrations and in the area under the concentration-time curve. Treatment with fenthion at 50 mg/kg, 7.4 times the average recommended rate, famphur at 75 mg/ kg, 3 times theAverage rate and chlorpyrifos at 85mg/kg caused reductions in whole blood cholinesterase activity of 52%, 27% and 47%.

ExcerptReferenceRelevance
"This fenthion pretreatment caused significant increases in the BPMC plasma concentrations and in the area under the concentration-time curve."( Potentiation of acute toxicity of 2-sec-butylphenyl N-methylcarbamate (BPMC) by fenthion in mice.
Miyaoka, T; Shirasu, Y; Takahashi, H; Tsuda, S, 1984
)
0.95
"Treatment with fenthion at 50 mg/kg, 7.4 times the average recommended rate, famphur at 75 mg/kg, 3 times the average rate and chlorpyrifos at 85 mg/kg, 5 times average rate, caused reductions in whole blood cholinesterase activity of 52%, 27% and 47% respectively which were similar to the reductions in cholinesterase activity found in calves treated with methidathion at similar levels above the recommended commercial dose rates."( Efficiency and safety of methidathion applied as a pour-on systemic insecticide for control of cattle lice.
Cavey, WA; Hart, RJ; Moore, B; Strong, MB, 1979
)
0.6

Toxicity

A pilot trial was conducted with fenthion 20% m/v to determine possible abortifacient or other toxic effects when applied to 4 1/2 month pregnant beef cows. The results showed that the acute toxicity of f tenthion belongs to highly toxic category.

ExcerptReferenceRelevance
"A pilot trial was conducted with fenthion 20% m/v to determine possible abortifacient or other toxic effects when applied to 4 1/2 month pregnant beef cows."( The safety of fenthion 29% m/v when applied topically to pregnant cows.
Joubert, JP; Minne, JA, 1979
)
0.9
" The only compound toxic to young mosquitofish at maximum field application rates was resmethrin."( Acute toxicity of mosquitocidal compounds to young mosquitofish, Gambusia affinis.
Hallmon, CF; Hester, PG; Olson, MA; Shaffer, KR; Tietze, NS, 1991
)
0.28
" The results showed that the acute toxicity of fenthion belongs to highly toxic category."( A study of the pesticide fenthion: toxicity, mutagenicity, and influence on tissue enzymes.
Bai, CL; Chen, YL; Qiao, CB; Qu, SX; Zhang, WD, 1990
)
0.84
" The approximate LD50 values calculated by this method showed little difference between two separate laboratories and were in good agreement with LD50 values reported in the literature."( A simple method for screening assessment of acute toxicity of chemicals.
Hashimoto, M; Kobayashi, K; Nishimura, M; Sekizawa, J; Tobe, M; Yamanaka, S, 1990
)
0.28
" Simultaneous administration of BPMC and either one of the thiophosphates (fenthion, its sulfoxide and sulfone) in a dose of 1/40 of its LD50 resulted in a 2- to 3-fold potentiation."( Mechanism of potentiation of BPMC toxicity by fenthion pretreatment in mice.
Miyaoka, T; Shirasu, Y; Tsuda, S, 1986
)
0.76
"Organophosphate compounds are very toxic chemicals and used in widespread applications."( Tissue trace and major element levels in organophosphate insecticide fenthion (Lebaycid) toxicity in rats: prophylactic and therapeutic effect of exogenous melatonin.
Aslan, A; Aymelek, F; Büyükben, A; Cemek, M; Emin Büyükokuroğlu, M; Yavuz, Y; Yürümez, Y, 2010
)
0.6

Pharmacokinetics

ExcerptReferenceRelevance
" This study describes a physiologically based pharmacokinetic (PBPK) model developed to simulate the absorption of organophosphate pesticides, such as parathion, fenthion, and methyl parathion through porcine skin with flow-through cells."( A physiologically based pharmacokinetic model of organophosphate dermal absorption.
Baynes, RE; Brooks, JD; Gehring, R; Monteiro-Riviere, NA; Riviere, JE; van der Merwe, D, 2006
)
0.53

Bioavailability

ExcerptReferenceRelevance
" To show the importance of physicochemical properties, the classic QSAR and CoMFA of neonicotinoids and prediction of bioavailability of pesticides in terms of membrane permeability in comparison with drugs are described."( Importance of physicochemical properties for the design of new pesticides.
Akamatsu, M, 2011
)
0.37
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

Fenthion (50 mg/kg) was administered subcutaneously twice a week for 1 year. A separate group of older (12 month) rats was exposed to the same dosing regimen and examined for neuropathological damage after 2 and 10 months exposure.

ExcerptRelevanceReference
" A separate group of older (12 month) rats was exposed to the same dosing regimen of Fenthion and examined for neuropathological damage after 2 and 10 months exposure."( The neurotoxicity of subchronic acetylcholinesterase (AChE) inhibition in rat hippocampus.
Jones, K; Pope, C; Veronesi, B, 1990
)
0.5
" Light microscopic evaluation revealed a dose-response relationship between the concentration of FEN (10(-2) M to 10(-5) M) and severity of morphologic changes."( Toxic effects of organophosphates on nerve cell growth and ultrastructure in culture.
Bowen, JM; Tuler, SM, 1989
)
0.28
" In this study, dogs were exposed to an OP (fenthion) by weekly dermal application of a 20% solution at a dosage of 44 mg/kg."( Neuromuscular effects of chronic exposure to fenthion in dogs and predictive value of electromyography.
Bowen, JM; Febles, D; Tuler, SM, 1988
)
0.8
" Doubling the diagnostic dosage of temephos for larval Ae."( Resistance in some Caribbean populations of Aedes aegypti to several insecticides.
Rawlins, SC; Wan, JO, 1995
)
0.29
" The assessment included the development of a classical dose-response 24-h assay and the incorporation of measurements of the effects on microbial activities in soil column leaching studies and multispecies miniaturised terrestrial systems (MTS)."( Rapid and cost-effective multiparameter toxicity tests for soil microorganisms.
Carbonell, G; Fernández, C; García, P; Pablos, MV; Ramos, C; Sánchez, P; Tarazona, JV, 2000
)
0.31
" The test group, having a mean of 186 ticks per dog, received the formulation dosage according to body weight on the neck region."( Analysis of the use of fenthion via epicutaneous in dogs for Rhipicephalus sanguineus control.
Fernandes, Fde F; Freitas, Ede P,
)
0.44
" Many patients do not understand how to correctly apply a transdermal dosage patch."( PATIENTS' KNOWLEDGE OF MEDICAL PATCHES IN HUNGARY.
Somogyi, O; Zelko, R, 2016
)
0.43
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (6)

RoleDescription
EC 3.1.1.7 (acetylcholinesterase) inhibitorAn EC 3.1.1.* (carboxylic ester hydrolase) inhibitor that interferes with the action of enzyme acetylcholinesterase (EC 3.1.1.7), which helps breaking down of acetylcholine into choline and acetic acid.
acaricideA substance used to destroy pests of the subclass Acari (mites and ticks).
agrochemicalAn agrochemical is a substance that is used in agriculture or horticulture.
avicideA substance used to destroy bird pests (class Aves).
EC 3.1.1.8 (cholinesterase) inhibitorAn EC 3.1.1.* (carboxylic ester hydrolase) inhibitor that interferes with the action of cholinesterase (EC 3.1.1.8).
insecticideStrictly, a substance intended to kill members of the class Insecta. In common usage, any substance used for preventing, destroying, repelling or controlling insects.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
organic thiophosphate
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (55)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency1.77830.003245.467312,589.2998AID2517
Chain A, HADH2 proteinHomo sapiens (human)Potency39.81070.025120.237639.8107AID886
Chain B, HADH2 proteinHomo sapiens (human)Potency39.81070.025120.237639.8107AID886
Chain A, JmjC domain-containing histone demethylation protein 3AHomo sapiens (human)Potency70.79460.631035.7641100.0000AID504339
LuciferasePhotinus pyralis (common eastern firefly)Potency43.74330.007215.758889.3584AID1224835; AID624030
acetylcholinesteraseHomo sapiens (human)Potency79.64070.002541.796015,848.9004AID1347398
RAR-related orphan receptor gammaMus musculus (house mouse)Potency29.84930.006038.004119,952.5996AID1159521; AID1159523
GLI family zinc finger 3Homo sapiens (human)Potency17.03640.000714.592883.7951AID1259369
AR proteinHomo sapiens (human)Potency24.41130.000221.22318,912.5098AID1259243; AID1259247; AID743054; AID743063
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency39.81070.011212.4002100.0000AID1030
thyroid stimulating hormone receptorHomo sapiens (human)Potency19.95260.001318.074339.8107AID926; AID938
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency31.43820.001022.650876.6163AID1224838; AID1224839; AID1224893
progesterone receptorHomo sapiens (human)Potency15.27110.000417.946075.1148AID1346795
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency6.16550.01237.983543.2770AID1645841
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency23.45120.003041.611522,387.1992AID1159552; AID1159553; AID1159555
pregnane X nuclear receptorHomo sapiens (human)Potency55.53830.005428.02631,258.9301AID1346982
estrogen nuclear receptor alphaHomo sapiens (human)Potency32.29140.000229.305416,493.5996AID1259244; AID588513; AID588514; AID743079; AID743080; AID743091
GVesicular stomatitis virusPotency3.89020.01238.964839.8107AID1645842
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency54.34330.001019.414170.9645AID743094
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency44.66840.035520.977089.1251AID504332
aryl hydrocarbon receptorHomo sapiens (human)Potency32.55160.000723.06741,258.9301AID651777; AID743085; AID743122
thyroid stimulating hormone receptorHomo sapiens (human)Potency26.81220.001628.015177.1139AID1224843; AID1224895; AID1259385; AID1259395
v-jun sarcoma virus 17 oncogene homolog (avian)Homo sapiens (human)Potency51.86760.057821.109761.2679AID1159528
chromobox protein homolog 1Homo sapiens (human)Potency79.43280.006026.168889.1251AID540317
thyroid hormone receptor beta isoform aHomo sapiens (human)Potency34.05380.010039.53711,122.0200AID588545; AID588547
potassium voltage-gated channel subfamily H member 2 isoform dHomo sapiens (human)Potency18.25630.01789.637444.6684AID588834
importin subunit beta-1 isoform 1Homo sapiens (human)Potency44.76805.804836.130665.1308AID540253; AID540263
snurportin-1Homo sapiens (human)Potency44.76805.804836.130665.1308AID540253; AID540263
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency58.03790.000627.21521,122.0200AID651741; AID720636; AID743202
GTP-binding nuclear protein Ran isoform 1Homo sapiens (human)Potency0.41095.804816.996225.9290AID540253
peripheral myelin protein 22Rattus norvegicus (Norway rat)Potency2.86950.005612.367736.1254AID624032
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency12.58930.031610.279239.8107AID884; AID885
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Voltage-dependent calcium channel gamma-2 subunitMus musculus (house mouse)Potency24.33650.001557.789015,848.9004AID1259244
Interferon betaHomo sapiens (human)Potency3.89020.00339.158239.8107AID1645842
HLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)Potency3.89020.01238.964839.8107AID1645842
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency24.33650.001551.739315,848.9004AID1259244
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Guanine nucleotide-binding protein GHomo sapiens (human)Potency50.11871.995325.532750.1187AID624287
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
GABA theta subunitRattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Inositol hexakisphosphate kinase 1Homo sapiens (human)Potency3.89020.01238.964839.8107AID1645842
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
cytochrome P450 2C9, partialHomo sapiens (human)Potency3.89020.01238.964839.8107AID1645842
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (50)

Processvia Protein(s)Taxonomy
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
positive regulation of T cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
adaptive immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independentHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of T cell anergyHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
defense responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
detection of bacteriumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-12 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-6 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protection from natural killer cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
innate immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of dendritic cell differentiationHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class IbHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
negative regulation of inflammatory response to antigenic stimulusGuanine nucleotide-binding protein GHomo sapiens (human)
renal water homeostasisGuanine nucleotide-binding protein GHomo sapiens (human)
G protein-coupled receptor signaling pathwayGuanine nucleotide-binding protein GHomo sapiens (human)
regulation of insulin secretionGuanine nucleotide-binding protein GHomo sapiens (human)
cellular response to glucagon stimulusGuanine nucleotide-binding protein GHomo sapiens (human)
inositol phosphate metabolic processInositol hexakisphosphate kinase 1Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
negative regulation of cold-induced thermogenesisInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (20)

Processvia Protein(s)Taxonomy
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
signaling receptor bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
peptide antigen bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein-folding chaperone bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
G protein activityGuanine nucleotide-binding protein GHomo sapiens (human)
adenylate cyclase activator activityGuanine nucleotide-binding protein GHomo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol heptakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
ATP bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 1-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 3-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (22)

Processvia Protein(s)Taxonomy
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
Golgi membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
endoplasmic reticulumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
Golgi apparatusHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
cell surfaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
ER to Golgi transport vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
secretory granule membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
phagocytic vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
early endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
recycling endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular exosomeHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
lumenal side of endoplasmic reticulum membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
MHC class I protein complexHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular spaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
external side of plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGuanine nucleotide-binding protein GHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
fibrillar centerInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
cytosolInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleusInositol hexakisphosphate kinase 1Homo sapiens (human)
cytoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (51)

Assay IDTitleYearJournalArticle
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1091957Apparent permeability of the compound by PAMPA2011Journal of agricultural and food chemistry, Apr-13, Volume: 59, Issue:7
Importance of physicochemical properties for the design of new pesticides.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1091955Dissociation constant, pKa of the compound at pH 7.32011Journal of agricultural and food chemistry, Apr-13, Volume: 59, Issue:7
Importance of physicochemical properties for the design of new pesticides.
AID1091958Hydrophobicity, log P of the compound in octanol-water by shaking-flask method2011Journal of agricultural and food chemistry, Apr-13, Volume: 59, Issue:7
Importance of physicochemical properties for the design of new pesticides.
AID1091956Apparent hydrophobicity, log D of the compound in Octanol-buffer2011Journal of agricultural and food chemistry, Apr-13, Volume: 59, Issue:7
Importance of physicochemical properties for the design of new pesticides.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (366)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990162 (44.26)18.7374
1990's68 (18.58)18.2507
2000's65 (17.76)29.6817
2010's49 (13.39)24.3611
2020's22 (6.01)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 31.23

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index31.23 (24.57)
Research Supply Index6.01 (2.92)
Research Growth Index4.42 (4.65)
Search Engine Demand Index70.53 (26.88)
Search Engine Supply Index3.24 (0.95)

This Compound (31.23)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials6 (1.50%)5.53%
Reviews12 (3.00%)6.00%
Case Studies29 (7.25%)4.05%
Observational0 (0.00%)0.25%
Other353 (88.25%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]